Obsidian Therapeutics (NASDAQ:OBX) Short Interest Update

Obsidian Therapeutics (NASDAQ:OBX) saw a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 36,102 shares, an increase of ∞ from the July 30th total of 0 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 46,658 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Several analysts have issued reports on OBX shares. Lifesci Capital initiated coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 target price on the stock. TD Cowen began coverage on shares of Obsidian Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating on the stock. Zacks Research upgraded shares of Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th. Finally, Piper Sandler initiated coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.50.

Obsidian Therapeutics Trading Down 4.3%

Shares of Obsidian Therapeutics stock traded down $0.74 during trading on Friday, hitting $16.30. The company’s stock had a trading volume of 260,517 shares, compared to its average volume of 153,125. Obsidian Therapeutics has a 52 week low of $14.57 and a 52 week high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.